Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.50 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429804 | 0.95 | CHRNB2 (0.52) | CHRNB2CHRNA4ORAI1KMT2AGRM2 | |
| SCHEMBL7101849 | 0.74 | CHRNB2 (0.81) | CHRNB2CHRNA4 | |
| SCHEMBL6586674 | 0.72 | MEN1 (0.43) | KMT2AMAPT | |
| SCHEMBL4888697 | 0.71 | CHRNB2 (0.62) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 | |
| SCHEMBL19055583 | 0.71 | CHRNB2 (0.62) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 | |
| SCHEMBL30542607 | 0.71 | CHRNB2 (0.62) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 | |
| SCHEMBL9367178 | 0.71 | CHRNB2 (0.62) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 | |
| SCHEMBL3229561 | 0.71 | CHRNB2 (0.62) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 | |
| SCHEMBL7105377 | 0.70 | CHRNB2 (0.84) | CHRNB2CHRNA4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29969480 | 0.70 | CHRNB2 (0.60) | CHRNB2CHRNA4KMT2ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| EP-1397355-A1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094813-A1 | NOVEL PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | CHRNB2 1463/4885CHRNA4 1435/4885ORAI1 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.